Please provide your email address to receive an email when new articles are posted on . Adbry is now available in the U.S. as a 300 mg/2 mL single-dose autoinjector for adults with atopic dermatitis.

Please provide your email address to receive an email when new articles are posted on . Adbry is approved for moderate to severe atopic dermatitis. The autoinjector delivers a single 300 mg/mL dose.

ADBRY ® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with ...

The new single-dose autoinjector is available in a 300mg/2mL dosage strength and is intended for use in adults only. The Food and Drug Administration (FDA) has approved a new single-dose autoinjector ...

LEO Pharma Inc. has today announced approval from the U.S. Food and Drug Administration (FDA) for a new Adbry® (tralokinumab-ldrm) 300 mg single-dose autoinjector for adult patients.1 Adbry, a ...

The single-dose 300 mg/2 mL autoinjector is now available as an additional injection choice when administering Adbry for the treatment of moderate-to-severe atopic dermatitis (AD) in adults.1 Adult ...

The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...